← GPCalc

NICE Osteoporosis Calculator

NICE NG259 Osteoporosis: risk assessment (July 2026) · treatment from NOGG 2024 and the BNF

Scenario

Patient

Fractures & steroids

Other risk factors

Risk tool & DXA

For choosing treatment

NICE-recommended plan

Enter age and sex to see the plan.

Decision support only. Assessment and treatment criteria follow NICE NG259 (2026), which replaced CG146; NG259 does not yet cover drug choice or treatment pauses, so these follow NOGG 2024 and the BNF/SPC. It does not replace clinical judgement or a FRAX/QFracture calculation.

Quick reference

Who to assess (NG259 1.1)
  • 50+ or postmenopausal: assess if previous fragility fracture or glucocorticoids (≥5 mg prednisolone >3 months or frequent courses). Consider if man ≥75, woman ≥65, or 50–74/postmenopausal with: ≥2 falls a year, family hip fracture, BMI <18.5, smoker, alcohol >14 units/week, or another risk condition or medicine.
  • Under 50, premenopausal or male: assess after a hip or vertebral fracture or ≥2 major osteoporotic fractures; consider after another fragility fracture, glucocorticoids or untreated early menopause/POI.
  • Risk tool: FRAX or QFracture (40–90), QFracture (30–39); specialist advice under 30 (1.3).
DXA, VFA and treatment criteria
  • Offer DXA (30+): hip or vertebral fracture, a major osteoporotic fracture in the last 2 years, or ≥2 fragility fractures (1.4.1). Consider DXA if 10-year MOF risk ≥10% (1.4.2).
  • VFA with DXA: consider in men ≥70, women ≥60, or younger with fracture, vertebral symptoms, steroids or Z-score <−2 (1.5).
  • Consider treatment (50+/postmenopausal): hip or vertebral fracture; ≥15 mg prednisolone ≥3 months; T-score ≤−2.5; or T-score ≤−1.5 with a fragility fracture, glucocorticoids or accelerated bone loss (1.7.3).
  • No treatment: MOF <10% → reassess at 5 years; otherwise repeat DXA in 2–3 years if close to threshold, else 5 years; never within 2 years (1.9, 1.10).

T-score: ≥−1 normal; −1 to −2.5 osteopenia; ≤−2.5 osteoporosis (WHO).

Treatment (NOGG 2024)
  • First line: alendronate or risedronate, or IV zoledronate; HRT for women ≤60 after menopause.
  • Very high risk (vertebral fracture in last 2 years, ≥2 vertebral fractures, T-score ≤−3.5, ≥7.5 mg prednisolone for 3 months): refer for parenteral/anabolic treatment.
  • Glucocorticoids ≥7.5 mg for ≥3 months: start bone protection at the same time.
  • Reassess after 5 years oral / 3 years IV. Continue if ≥70, hip or vertebral fracture, high-dose steroids or fracture on treatment; otherwise consider an 18–36 month pause.
  • Never stop denosumab without a follow-on plan.